PIK3CA mutations and PTEN loss: Effects on neoadjuvant trastuzumab in Vietnamese breast cancer patients
Author:
Publisher
Polaris
Reference15 articles.
1. da Luz FA, da Costa Marinho E, Nascimento CP, de Andrade Marques L, Delfino PF, Antonioli RM, et al. The benefits of trastuzumab in the treatment of HER2+ breast cancer as a function of exposure time. Ecancermedicalscience. 2022;16:1347.
2. Nishimura R, Arima N, Toyoshima S, Ohi Y, Anan K, Sagara Y, et al. Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001). Mol Clin Oncol. 2013;1(1):47-52.
3. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194-220.
4. Shi Q, Xuhong J, Luo T, Ge J, Liu F, Lan Y, et al. PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer. Br J Cancer. 2023;128(1):121-9.
5. Golmohammadi R, Rakhshani MH, Moslem AR, Pejhan A. Prognostic role of PTEN gene expression in breast cancer patients from north-east Iran. Asian Pac J Cancer Prev. 2016;17(9):4527-31.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3